Sign In
Buy GRCL
$10.25
+0 (+0%)
At Close: May 20, 2024
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
08:30am, Wednesday, 14'th Sep 2022
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China , Sept.
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
08:00am, Tuesday, 14'th Jun 2022
SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , June.
SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China , May 26, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical comp
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
08:30am, Thursday, 19'th May 2022
SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, May 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to disc
Gracell Biotechnologies Inc. (GRCL) CEO Dr. William Cao on Q1 2022 Results - Earnings Call Transcript
02:23pm, Monday, 16'th May 2022
Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q1 2022 Earnings Conference Call May 16, 2022 8:00 AM ET Company Participants Dr. William Cao - Founder, Chairman, and CEO Dr. Martina Sersch - CMO Dr. Kevi
SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , May 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company
Allogeneic, off-the-shelf CAR-T therapy with CD19/CD7 dual-directed CAR shows promising early results in patients with r/r B-ALL PALO ALTO, Calif. and SUZHOU, China , April 8, 2022 /PRNewswire/ -- Gra
Gracell Biotechnologies to Participate in Three Investor Conferences in April
08:30am, Tuesday, 29'th Mar 2022
PALO ALTO, Calif. and SUZHOU, China, March 29, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to disc
Gracell Biotechnologies, Inc. (GRCL) CEO Dr. William Cao on Q4 2021 Results - Earnings Call Transcript
04:20pm, Monday, 14'th Mar 2022 Seeking Alpha
Gracell Biotechnologies Inc. 2021 Q4 - Results - Earnings Call Presentation
02:35pm, Monday, 14'th Mar 2022 Seeking AlphaGracell Biotechnologies, Inc. (GRCL) CEO Dr. William Cao on Q4 2021 Results - Earnings Call Transcript
12:20pm, Monday, 14'th Mar 2022
Gracell Biotechnologies, Inc. (GRCL) CEO Dr. William Cao on Q4 2021 Results - Earnings Call Transcript
Gracell Biotechnologies: Q4 Earnings Insights
12:12pm, Monday, 14'th Mar 2022 Benzinga
Gracell Biotechnologies (NASDAQ: GRCL ) reported its Q4 earnings results on Monday, March 14, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Gracell Biotechnologies beat estimated earnings by 9.09%, reporting … Full story available on Benzinga.com
Gracell Biotechnologies GAAP EPS of -$0.06 beats by $0.10
11:32am, Monday, 14'th Mar 2022 Seeking Alpha
Gracell Biotechnologies press release (GRCL): Q4 GAAP EPS of -$0.06 beats by $0.10.As of December 31, 2021, the Company had RMB1,832.6 million (US$287.6 million) in cash and…
Gracell Biotechnologies to Participate in Oppenheimer 32nd Annual Healthcare Conference
09:30pm, Thursday, 10'th Mar 2022 GlobeNewswire
PALO ALTO, Calif. and SUZHOU, China, March 10, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Oppenheimer 32 nd Annual Healthcare Conference from March 15 th to 17 th .
Gracell Biotechnologies to Report Fourth Quarter & Full Year 2021 Financial Results on Monday, March 14, 2022
08:00am, Wednesday, 02'nd Mar 2022
PALO ALTO, Calif. and SUZHOU, China, March 02, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to deve
